Randomized Trialmoderate evidence
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.
Pharmaceuticals (Basel, Switzerland)·September 21, 2026·PMID 42797541
Why it mattersLow-dose psilocybin may offer a scalable, outpatient-compatible approach for psychiatric and wellness applications if therapeutic benefits can be achieved without hallucinogenic or cognitive effects. This study provides early safety and pharmacodynamic data supporting further investigation of subperceptual dosing.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled